Table 2.

Association between 16 reported prostate cancer susceptibility SNPs with prostate cancer–specific survival

Marker SNPChromosomePosition*Alleles
Frequency of risk alleleHR (95% CI)P
ReferenceRisk allele
rs7210482p1563043382GA0.201.10 (0.93-1.30)0.25
rs26607533p1287193364CT0.101.15 (0.92-1.44)0.21
rs93645546q2516075365CT0.330.97 (0.84-1.12)0.63
rs104865677p1527943088TC0.780.96 (0.82-1.13)0.64
rs64656577q2197654263TC0.510.87 (0.75-1.00)0.05
rs169019798q24 (2)128194098CA0.060.89 (0.67-1.18)0.41
rs69832678q24 (3)128482487TG0.561.04 (0.91-1.19)0.58
rs14472958q24 (1)128554220CA0.170.95 (0.79-1.15)0.62
rs15718019q33121506927GT0.310.88 (0.75-1.03)0.11
rs1099399410q1151219502CT0.430.94 (0.82-1.08)0.39
rs496241610q26126686862AG0.240.96 (0.82-1.13)0.65
rs1089644911q1368751243AG0.490.99 (0.86-1.13)0.83
rs443079617q1233172153CT0.610.91 (0.79-1.05)0.20
rs185996217q2466620348TG0.541.03 (0.89-1.18)0.69
rs273583919q1356056435AG0.880.94 (0.77-1.15)0.54
rs5945619Xp1151258412AG0.420.88 (0.72-1.07)0.20
  • NOTE: Association between genotypes and prostate cancer–specific survival was assessed in a Cox regression model assuming an additive genetic effect. In each regression model, covariates representing age, clinical stage, biopsy Gleason sum, diagnostic serum PSA level, and nodal and distal metastases were included.

    Abbreviations: HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.

  • * Based on build 35.

  • Risk alleles are based on previously published studies.

  • P value from a score test in Cox regression analysis.